Clinical Trial Update: Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Lu-177 labeled PSMA-targeted radioligand PNT2002 for metastatic castration-resistant prostate cancer after second-line hormonal therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lu-177-PSMA PNT2002 (PNT2002)

Snippet

Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-01-13